At Acrigen, we believe that gene editing will revolutionize medicine and bring hope to millions of patients suffering from genetic diseases. We are developing Precision Gene Editing Systems to harness the power of CRISPR for use in human therapeutics. Acrigen’s proprietary technology leverages novel αCas and μCas CRISPR gene editors coupled with ErAcrs (engineered anti-CRISPR proteins) to create an editing toolbox with best-in-class efficiency and precision. Acrigen has discovered and engineered αCas and μCas, 2 families of novel CRISPR-Cas nucleases fine tuned for human gene editing.
Berkeley, United States
Founded in 2019
1-10 Employees
Working industry
Biotechnology
Type of company
Manufacturer
Ownership structure
Privately Held
Locations
1 Headquarter
Number of products
1 Product
Specialised areas
Biotechnology, Genetics, Life Science
Acrigen Biosciences offers a wide range of products and services
Product
Our Technology — Acrigen Biosciences
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Acrigen Biosciences operates in 1 country around the world
Get an overview of the locations of Acrigen Biosciences
Location
Country
State
City
Headquarter
United States
California
Berkeley
Some frequent questions that have been asked about Acrigen Biosciences
Where is Acrigen Biosciences located?
The company headquarter of Acrigen Biosciences is located in Berkeley, California, United States. It's worth noting, that the company may have more locations
How many employees does Acrigen Biosciences approximately have?
As of the latest available information Acrigen Biosciences has around 1-10 employees worldwide.
When was Acrigen Biosciences founded?
Acrigen Biosciences was founded in 2019
In which industries does Acrigen Biosciences mainly work?
The company Acrigen Biosciences has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Acrigen Biosciences
Algen Biotechnologies
San Francisco, United States
1-10 Employees
2018
We are on a groundbreaking journey to redefine possibilities in biology. AlgenCRISPR is a proprietary, next-generation CRISPR system developed by Algen. Our best-in-class technology offers robust, fine-tuned and precise gene modulation to deconvolute complex biology. Algen’s proprietary deep learning models are built on billions of real-time, dynamic gene expression changes that occur throughout disease progression.
Emendo Biotherapeutics
New York, United States
11-50 Employees
2015
We boldly create novel and elegant CRISPR solutions to make a positive and profound impact on human health. From the very start we knew that CRISPR had the potential to cure the most complex genetic diseases, but limitations of the original CRISPR-Cas9 system prevented this vision from being fully realized. So we flipped the CRISPR script to first understand each genetic disease and then devise an optimal editing strategy. At EmendoBio, we’ve brought together a world class multifaceted team to evolve traditional CRISPR tools and create entirely new nucleases customized to any genetic disease. We come to work knowing every challenge we face can be overcome.
Precision BioSciences
Durham, United States
101-250 Employees
2006
At Precision BioSciences we are using our novel ARCUS genome editing technology to develop a new class of medicines designed to overcome and potentially cure, hard-to-treat conditions including rare genetic diseases. Our team is built on a foundation of innovation and scientific discovery, and all employees at the company, whom we passionately refer to as Precisioneers, share in our mission – Dedicated to Improving Life – and our values:. ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at Precision BioSciences.
CRISPR Therapeutics
Cambridge, United States
101-250 Employees
2013
We are pioneering a new era of medicines. We are pioneers of the CRISPR technology and at the forefront of what’s next. The first-ever CRISPR-based therapy is a direct reflection of our patient-forward philosophy. We believe this once-in-a-generation breakthrough will make an impact for generations to come. CRISPR Therapeutics is founded, launching the growth of our team focused on translating the CRISPR/Cas9 discovery into potential therapeutics. Opens the doors to its own manufacturing facility in Framingham, Massachusetts. Where we’ve built our state-of-the-art, award-winning manufacturing facility.*. Here we focus on the most advanced gene editing and delivery technologies of the future.
Scribe Therapeutics
United States
11-50 Employees
2017
Join our mission to engineer the next 20 years of gene editing breakthroughs - today. Pioneering novel viral and non-viral delivery technologies to truly enable in vivo genetic medicine. Built for exceptional specificity within the genome – enabling therapeutic precision and allele specific targeting.
Hunterian Medicine
Cambridge, United States
1-10 Employees
2016
The Hunterian technology uses a novel genetic element to enable in vivo delivery via a single adeno-associated virus (AAV). Hunterian Medicine is a gene editing company poised to unleash the full potential of CRISPR. Hunterian Medicine’s technology opens an immediate path to develop cures for a vast number of genetic diseases where no FDA approved therapies exist. Hunterian Medicine’s technology uses a novel “2-for-1” genetic control element, a bidirectional promoter, to overcome the challenge of delivering CRISPR via AAV. Hunterian's approach has the immediate potential to bring multiple CRISPR technologies to the clinic and dramatically accelerate the development of CRISPR-based therapeutics. CRISPR is a revolutionary gene-editing tool with the ability to edit nearly any DNA sequence within the human genome, and the potential to correct a multitude of disease-causing mutations. Our patented platform technology solves the CRISPR delivery problem by enabling efficient, on-target delivery through a single adeno-associated virus (AAV). By freeing up critical space in AAV, Hunterian Medicine’s technology allows for the development of the safest and most effective CRISPR-based therapeutics.